NO960723L - Inhibitors of TNF-alpha secretion - Google Patents

Inhibitors of TNF-alpha secretion

Info

Publication number
NO960723L
NO960723L NO960723A NO960723A NO960723L NO 960723 L NO960723 L NO 960723L NO 960723 A NO960723 A NO 960723A NO 960723 A NO960723 A NO 960723A NO 960723 L NO960723 L NO 960723L
Authority
NO
Norway
Prior art keywords
tnf
inhibitors
alpha secretion
tace
compounds
Prior art date
Application number
NO960723A
Other languages
Norwegian (no)
Other versions
NO960723D0 (en
Inventor
Roy Alvin Black
Jeffrey Neal Fitzner
Paul Ronald Sleath
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of NO960723L publication Critical patent/NO960723L/en
Publication of NO960723D0 publication Critical patent/NO960723D0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Det er beskrevet forbindelser og fremgangsmåter som kan anvendes til inhibering av det TNF-a-omdannende enzym (TACE) som er ansvarlig for spalting av TNF-ct-forløper, hvorved det fås biologisk aktiv TNF-a. Forbindel- sene som anvendes ved oppfinnelsen, er peptidylderivater med aktive grupper som er i stand til å inhibere TACE, slik som hydroksamater, tioler, fosfo- ryler og karboksyler.Compounds and methods are described which can be used to inhibit the TNF-α converting enzyme (TACE) responsible for cleavage of TNF-ct precursor to give biologically active TNF-α. The compounds used in the invention are peptidyl derivatives with active groups capable of inhibiting TACE such as hydroxamates, thiols, phosphoryls and carboxyls.

NO960723A 1993-08-23 1996-02-23 Inhibitors of TNF-alpha secretion NO960723D0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11060193A 1993-08-23 1993-08-23
US18301994A 1994-01-18 1994-01-18
PCT/US1994/009343 WO1995006031A1 (en) 1993-08-23 1994-08-19 Inhibitors of tnf-alpha secretion

Publications (2)

Publication Number Publication Date
NO960723L true NO960723L (en) 1996-02-23
NO960723D0 NO960723D0 (en) 1996-02-23

Family

ID=26808203

Family Applications (1)

Application Number Title Priority Date Filing Date
NO960723A NO960723D0 (en) 1993-08-23 1996-02-23 Inhibitors of TNF-alpha secretion

Country Status (8)

Country Link
EP (1) EP0715619A4 (en)
JP (1) JPH09503201A (en)
AU (2) AU687436B2 (en)
CA (1) CA2170158A1 (en)
FI (1) FI960803A (en)
NO (1) NO960723D0 (en)
NZ (1) NZ271893A (en)
WO (1) WO1995006031A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0784629T3 (en) 1994-10-05 1999-10-25 Darwin Discovery Ltd Peptidyl compounds and their therapeutic use as inhibitors of metalloproteases
US5994293A (en) * 1995-05-10 1999-11-30 Darwin Discovery Ltd. Peptidyl compounds and their therapeutic use
EP0824543A1 (en) * 1995-05-10 1998-02-25 Chiroscience Limited Peptide compounds which inhibit metalloproteinase and tnf liberation, and their therapeutic use
CA2217857A1 (en) * 1995-05-10 1996-11-14 Darwin Discovery Limited Peptide compounds which inhibit metalloproteinase and tnf liberation and their therapeutic uses
US6406901B1 (en) 1995-06-08 2002-06-18 Immunex Corporation TNF-a converting enzyme
WO1997009420A2 (en) * 1995-09-05 1997-03-13 Celltech Therapeutics Limited Dna sequences coding for a human metalloproteinase and variants thereof
HUP0003760A3 (en) * 1995-10-05 2001-05-28 Darwin Discovery Ltd Cambridge Thio-substituted peptides as inhibitors for metalloproteinases and tnf liberation, process for production thereof and their use
US5665777A (en) * 1995-11-14 1997-09-09 Abbott Laboratories Biphenyl hydroxamate inhibitors of matrix metalloproteinases
NZ322553A (en) 1995-11-23 1998-12-23 British Biotech Pharm Metalloproteinase inhibitors
GB9607120D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
US5990293A (en) * 1996-09-05 1999-11-23 Celltech Therapeutics Limited Human metalloproteinase, variants thereof and DNA sequence coding therefor
PL191366B1 (en) 1996-09-10 2006-05-31 Vernalis Oxford Ltd Cytostatic derivatives of hydroxamic acid
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
ZA9818B (en) * 1997-01-07 1998-07-02 Abbott Lab C-terminal ketone inhibitors of matrix metalloproteinases and tnf alpha secretion
AU730308B2 (en) * 1997-06-18 2001-03-01 Rockefeller University, The Methods for identifying antibodies and peptides useful in the treatment of septic shock and experimental arthritis and uses thereof
EP1021173A1 (en) * 1997-10-10 2000-07-26 Imperial College Innovations Limited Use of csaid?tm compounds for the management of uterine contractions
GB9810464D0 (en) * 1998-05-16 1998-07-15 British Biotech Pharm Hydroxamic acid derivatives
US6172064B1 (en) 1998-08-26 2001-01-09 Glaxo Wellcome Inc. Formamides as therapeutic agents
US6329400B1 (en) 1998-08-26 2001-12-11 Glaxo Wellcome Inc. Formamide compounds as therapeutic agents
GB9818605D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Formamide compounds as therepeutic agents
WO2000018361A2 (en) * 1998-09-30 2000-04-06 The Procter & Gamble Company Method of treating hair loss using sulfonamides
BR9914197A (en) * 1998-09-30 2001-07-03 Procter & Gamble Hair loss treatment process with the use of ketoamides
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
US6329550B1 (en) 1998-12-31 2001-12-11 Aventis Pharmaceuticals Inc. Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase
JP2002534440A (en) * 1999-01-13 2002-10-15 ヨマー、ファルマカ、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツング Use of 3-isoxazolidinone and hydroxylamic acid for the treatment of infectious diseases
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
GB9922825D0 (en) * 1999-09-25 1999-11-24 Smithkline Beecham Biolog Medical use
AU2001271068A1 (en) * 2000-07-18 2002-01-30 Chugai Seiyaku Kabushiki Kaisha Matrix metalloprotease inhibitors
WO2002028829A2 (en) * 2000-09-25 2002-04-11 Questcor Pharmaceuticals, Inc. Peptide deformylase inhibitors
PE20030701A1 (en) 2001-12-20 2003-08-21 Schering Corp COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
BR112021006407A8 (en) 2018-10-04 2022-12-06 Inst Nat Sante Rech Med use of egfr inhibitors for keratoderms

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986003747A1 (en) * 1984-12-19 1986-07-03 Ciba-Geigy Ag New carbonic acid esters
FR2609289B1 (en) * 1987-01-06 1991-03-29 Bellon Labor Sa Roger NOVEL COMPOUNDS HAVING ACTIVITY OF COLLAGENASE INHIBITORS, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
AU2228292A (en) * 1991-06-14 1993-01-12 Research Corporation Technologies, Inc. Peptide derivatives of collagenase inhibitor
GB9215665D0 (en) * 1992-07-23 1992-09-09 British Bio Technology Compounds
GB9323165D0 (en) * 1993-11-10 1994-01-05 Chiros Ltd Compounds
GB9411088D0 (en) * 1994-06-03 1994-07-27 Hoffmann La Roche Hydroxylamine derivatives

Also Published As

Publication number Publication date
AU687436B2 (en) 1998-02-26
FI960803A0 (en) 1996-02-22
JPH09503201A (en) 1997-03-31
FI960803A (en) 1996-04-22
AU7569494A (en) 1995-03-21
AU5030298A (en) 1998-03-05
WO1995006031A1 (en) 1995-03-02
CA2170158A1 (en) 1995-03-02
NZ271893A (en) 1997-11-24
EP0715619A4 (en) 1997-03-19
NO960723D0 (en) 1996-02-23
EP0715619A1 (en) 1996-06-12

Similar Documents

Publication Publication Date Title
NO960723L (en) Inhibitors of TNF-alpha secretion
MY129998A (en) Saccharin derivative proteolytic enzyme inhibitors
Harris et al. Pseudosubstrate inhibition of cyclic AMP-dependent protein kinase in intact pancreatic islets: effects on cyclic AMP-dependent and glucose-dependent insulin secretion
MY110104A (en) Saccharin derivative proteolytic enzyme inhibitors
BR9908280A (en) Phospholipase enzyme inhibitors
TR200103216T2 (en) Pyrimidinone compositions
AU2002357312A1 (en) Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases
PT691988E (en) INHIBITOR OF PROLIFERATION OF STELLIC CELLS AND THEIR UTILIZATIONS
MD1507G2 (en) Inhibitors, pharmaceutical composition on base thereof and process for HIV protease inhibition
DK0938570T3 (en) Mutated alpha-amylase comprising modification at residues corresponding to A210, H405 and / or T412 in Bacillus licheniformis
AU2001248701A1 (en) Inhibitors of histone deacetylase
NZ503962A (en) ACE inhibitor (angiotensin converting enzyme) and MMP (matrix metalloproteinase inhibitor) combinations for treating fibrosis
PT784677E (en) INHIBITOR OF PROLIFERACAOD STEM CELLS AND THEIR UTILIZATIONS
NO981520D0 (en) Thiosubstituted peptides as inhibitors of metalloproteinases and TNF release
NO914217D0 (en) SUGAR CARE DERIVATIVES USED AS PROTEOLYTIC ENZYMIN INHIBITORS AND MANUFACTURING THEREOF
AU2002325782A1 (en) Pharmaceutical composition and method of treatment of human malignancies with arginine deprivation
WO2004052236A3 (en) Methods and compositions for treatment of otitis media
DE59009945D1 (en) AGENT FOR INHIBITING HIV PROTEASES.
Kress et al. Effects of human plasma α2 macroglobulin on the proteolytic activity of snake venoms
Murachi et al. Inhibition of stem bromelain by the chloromethyl ketone derivatives of N-tosyl-L-phenylalanine and N-tosyl-L-lysine
AU2158200A (en) Novel inhibitors of farnesyl-protein transferase
Petrovan et al. Purification and characterization of multisquamase, the prothrombin activator present in Echis multisquamatus venom
DK0977495T3 (en) Composition containing pectin methyl esterase and two substrates
NO951277L (en) High molecular weight desulfatohirudin
AU2001260314A1 (en) Method for selecting enzyme inhibitors